[English]  [Pусский]  [中文]  
 
ctt-journal > Zagoskina et al. (Abstract)

Zagoskina et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract47

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Immunochemotherapy results in patients with relapsed and refractory chronic lymphocytic leukemia

Tamara P. Zagoskina, Ekaterina N. Zotina, Olga V. Malykh, Valentina T. Demyanova

FGI "Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia", Kirov, Russia

Correspondence: Tamara P. Zagoskina, FGI "Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia", 72, Krasnoarmeiskaya str., 610027, Kirov, Russia, E-mail: zagoskina@spam is badblood.kirov.ru

Abstract

A new treatment option of chronic lymphocytic leukemia (CLL) is the use of monoclonal anti-CD52 antibody (alemtuzumab).

Aim: To study the efficiency and toxicity of a combination of fludarabine with alemtuzumab in relapsed and refractory CLL.

Materials and methods: Twenty-one CLL patients (17 male and 4 female) were included in the study. The age of patients ranged from 35 to 72 years (median 56 years). Sixteen patients were in stage В and 5 in stage С according to the Binet classification. Nine patients were refractory to the previously registered therapy; 12 CLL patients were in relapse. Prior therapy included alkylating agents and/or treatment fludarabine-containing regimens (FC, RFC, and FCM).

Results: With the use of fludarabine with alemtuzumab (FluCam) as 2–4 line therapy, an overall response was observed in 16 (76%) patients: complete remission (CR) was achieved in 6 (28%) patients, and partial remission (PR) in 10 (48%). Disease progression was observed in 1 (5%) patient, and stabilization of the process in 4 (19%). It is necessary to note that in 4 (19%) patients with complete clinical and morphological remission, immunophenotypic remission developed too. A median overall survival of patients over the period was not reached. The median progression-free survival in patients with CR was 21 months, and patients with PR, 8 months. The most common manifestations of hematologic toxicity were thrombocytopenia (52%) and neutropenia (43%), mostly of 1–2 degrees. Infectious complications occurred in 11 (52%) patients, 36% patients of them were identified with asymptomatic сytomegalovirus reactivation. All side effects were manageable with adequate supportive therapy.

Conclusion: The combination of FluCam is an effective treatment regimen for patients with relapsed and refractory CLL, with an acceptable toxicity. The main side effects of treatment include infectious complications, mainly in the form of asymptomatic cytomegalovirus reactivation.

Keywords: chronic lymphocytic leukemia, refractory, relapse, alemtuzumab, fludarabine